BRIEF published on 10/06/2026 at 22:10, 2 days 19 hours ago Inventiva reveals progress at the AASLD The Liver Meeting 2026 Inventiva Lanifibranor MASH Treatment AASLD 2026 PPAR Activation
BRIEF published on 10/06/2026 at 22:10, 2 days 19 hours ago Inventiva to Present Abstracts at 2026 Liver Meeting Inventiva MASH Lanifibranor PPAR Liver Meeting® 2026
PRESS RELEASE published on 10/06/2026 at 22:05, 2 days 19 hours ago Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 Inventiva to present scientific abstracts on lanifibranor at AASLD The Liver Meeting® 2026, focusing on PPAR isoforms and epigenetic changes in MASH pathogenesis Inventiva MASH Lanifibranor AASLD PPAR Isoforms
BRIEF published on 09/08/2026 at 22:05, 1 month ago Inventiva to Showcase Lanifibranor Data at Paris MASH 2026 Clinical Data Inventiva MASH Lanifibranor PPAR Agonist
BRIEF published on 09/08/2026 at 22:05, 1 month ago Inventiva presents its advancements at the Paris MASH 2026 Congress Inventiva MASH Lanifibranor Clinical Phase PPAR
PRESS RELEASE published on 09/08/2026 at 22:00, 1 month ago Inventiva to Present Multiple Abstracts at Paris MASH 2026 Inventiva to present Phase 1 and Phase 2 clinical data on lanifibranor at Paris MASH 2026, showing improvements in metabolic and cardiovascular factors in MASH patients. Lanifibranor's pan-PPAR pharmacology highlighted Clinical Data Inventiva Lanifibranor Metabolic Dysfunction Paris MASH 2026
BRIEF published on 09/02/2026 at 22:10, 1 month 6 days ago Inventiva Completes Final Visit of the NATiV3 Lanifibranor Study Clinical Study Phase 3 Inventiva MASH Lanifibranor
BRIEF published on 09/02/2026 at 22:10, 1 month 6 days ago Inventiva Completes Key Milestone in MASH Clinical Trial Biopharmaceutical Inventiva Lanifibranor MASH Treatment NATiV3 Trial
PRESS RELEASE published on 09/02/2026 at 22:05, 1 month 6 days ago Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH Inventiva completes last patient visit in Phase 3 trial for lanifibranor in MASH treatment, with topline results expected in Q4 2026. Financial results update scheduled for H1 2026 Phase 3 Trial Inventiva Lanifibranor MASH Treatment Financial Results Update
BRIEF published on 08/31/2026 at 22:10, 1 month 8 days ago Chris Benecchi appointed COO by Inventiva Biopharmaceutical Inventiva MASH Lanifibranor Chris Benecchi
Published on 10/09/2026 at 14:00, 3 hours 37 minutes ago Stillwater Critical Minerals Upgrades to OTCQX Best Market, Expanding U.S. Market Presence
Published on 10/09/2026 at 14:00, 3 hours 37 minutes ago Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Published on 10/09/2026 at 13:23, 4 hours 14 minutes ago SLAM Exploration Announces Leadership Transition and Appointment of Jimmy Gravel as President and CEO
Published on 10/09/2026 at 13:00, 4 hours 37 minutes ago Horizon Aircraft Reports Fiscal 2027 First Quarter Results and Advances Full-Scale Cavorite X7 Development
Published on 10/09/2026 at 13:00, 4 hours 37 minutes ago Nepra Foods Launches Flagship PROPASTA Brand on Amazon
Published on 10/09/2026 at 17:15, 21 minutes ago OPPO Find X10 Pro Max to Debut Globally with MediaTek’s 2nm Flagship Dimensity 9600 Pro
Published on 10/09/2026 at 17:10, 26 minutes ago "Soaring Creativity - Hong Kong Pavilion" Returns to Frankfurt Book Fair 2026, Showcasing Over 1,000 Masterpieces
Published on 10/09/2026 at 15:55, 1 hour 42 minutes ago Bio-Gate AG reports first half results for 2026
Published on 10/09/2026 at 15:53, 1 hour 43 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 10/08/2026 at 18:30, 23 hours 7 minutes ago Cegedim: Release of its 2026 Interim Financial Report
Published on 10/08/2026 at 18:00, 23 hours 37 minutes ago Launch of LINK, the next generation of THIN: Clinityx’s first European Health Data Warehouse, approved by the French Data Protection Authority for 10 years
Published on 10/08/2026 at 17:45, 23 hours 52 minutes ago Carrefour announces a real estate sale and leaseback transaction involving 35 stores in France and Spain
Published on 10/07/2026 at 18:19, 1 day 23 hours ago Outstanding shares and voting rights statement at 30 September 2026
